WO2022107044 - PREVENTION AND/OR TREATMENT OF CNS DISORDERS
National phase entry:
Publication Number
WO/2022/107044
Publication Date
27.05.2022
International Application No.
PCT/IB2021/060709
International Filing Date
18.11.2021
Title **
[English]
PREVENTION AND/OR TREATMENT OF CNS DISORDERS
[French]
PRÉVENTION ET/OU TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL
Applicants **
ILDONG PHARMACEUTICAL CO., LTD.
2, Baumoe-ro 27 gil, Seocho-gu
Seoul 06752, KR
Inventors
KIM, Kyung-Sun
c/o ILDONG PHARMACEUTICAL CO., LTD.
2, Baumoe-ro 27-gil, Seocho-gu
Seoul 06752, KR
KIM, Jeong-Ah
c/o ILDONG PHARMACEUTICAL CO., LTD.
2, Baumoe-ro 27-gil, Seocho-gu
Seoul 06752, KR
MOON, An-Na
c/o ILDONG PHARMACEUTICAL CO., LTD.
2, Baumoe-ro 27-gil, Seocho-gu
Seoul 06752, KR
SONG, Dong-Keun
c/o ILDONG PHARMACEUTICAL CO., LTD.
2, Baumoe-ro 27-gil, Seocho-gu
Seoul 06752, KR
LEE, Yoon-Suk
c/o ILDONG PHARMACEUTICAL CO., LTD.
2, Baumoe-ro 27-gil, Seocho-gu
Seoul 06752, KR
JUNG, Ju-young
c/o ILDONG PHARMACEUTICAL CO., LTD.
2, Baumoe-ro 27-gil, Seocho-gu
Seoul 06752, KR
Priority Data
63/115,972
19.11.2020
US
17/528,342
17.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1833 | |
| EPO | Filing, Examination | 10749 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 4310 |
Total: 18090 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds are disclosed. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease. The compounds and compositions may also find use in various therapeutic applications including the treatment of cancer and in immuno-oncology.[French]
Des composés antagonistes du récepteur de l'adénosine (par exemple, des composés antagonistes du récepteur A2A et/ou A1) et des compositions comprenant lesdits composés sont divulgués. La présente divulgation concerne également des méthodes d'utilisation desdits composés et compositions pour moduler (par exemple, inhiber ou antagoniser) le récepteur A2A et/ou A1 dans un système biologique. Les composés et les compositions trouvent une utilisation dans diverses applications thérapeutiques, notamment dans le traitement du système nerveux central ou de maladies neurodégénératives, telles que la maladie de Parkinson. Les composés et les compositions peuvent également être utilisés dans diverses applications thérapeutiques, notamment dans le traitement du cancer et en immuno-oncologie.